Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 3/20 | 0.62 |
| ▸ | ATP4B | P51164 | 3/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.52 |
| ▸ | RARB | P10826 | 7/20 | 0.50 |
| ▸ | RARG | P13631 | 3/20 | 0.50 |
| ▸ | RARA | P10276 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207159 | 0.84 | DHODH (0.48) | ATP4AATP4BPLA2G4BRARBPTPN1 | |
| SCHEMBL2697298 | 0.84 | DHODH (0.48) | ATP4AATP4BPLA2G4BRARBPTPN1 | |
| SCHEMBL10612521 | 0.80 | RARB (0.72) | PLA2G4BRARBPLA2G4A | |
| SCHEMBL15199296 | 0.79 | PLA2G4B (0.76) | PLA2G4BRARBPLA2G4A | |
| SCHEMBL9163844 | 0.79 | PLA2G4B (0.76) | PLA2G4BRARBPLA2G4A | |
| SCHEMBL11842813 | 0.79 | PLA2G4B (0.76) | PLA2G4BRARBPLA2G4A | |
| SCHEMBL7369439 | 0.79 | PLA2G4B (0.76) | PLA2G4BRARBPLA2G4A | |
| SCHEMBL206829 | 0.78 | PTPRC (0.49) | PTPN1PLA2G4A | |
| SCHEMBL207114 | 0.78 | PTPRC (0.49) | PTPN1PLA2G4A | |
| SCHEMBL8744429 | 0.78 | PLA2G4B (0.73) | PLA2G4BRARBPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | ATP4A 977/4885ATP4B 1788/4885PLA2G4B 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.